An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Phase 2
- Conditions
- Small Cell Lung CancerDurvalumabLung Cancer
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 60
- Registration Number
- NCT05245994
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance
Phase 2
Recruiting
- Conditions
- Second Generation ALK-TKI is ResistantThe Diagnosis Was ALK Positive NSCLCEfficacy of Ensatinib in This Subset of Patients
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 40
- Registration Number
- NCT05178511
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 106
- Registration Number
- NCT05003037
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guang Dong, China
Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations
Phase 3
- Conditions
- Non-small Cell CarcinomaEGFR Gene Mutation
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 291
- Registration Number
- NCT04695925
- Locations
- 🇨🇳
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University, Guangzhou, Guangdong, China
JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.
Phase 2
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Li Zhang, MD
- Target Recruit Count
- 50
- Registration Number
- NCT04459663
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath